Stockreport

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics, Inc.  (IPSC) 
PDF – Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include add [Read more]